Stock Track | Supernus Pharmaceuticals Soars 8.22% Intraday on Better-Than-Expected Q4 Results and Strong Guidance

Stock Track02-25

Supernus Pharmaceuticals' stock surged 8.22% during intraday trading on Wednesday, driven by the company's fourth-quarter financial results that exceeded analyst expectations and optimistic revenue guidance for 2026.

The pharmaceutical company reported a Q4 loss of $0.07 per diluted share, which was better than the $0.08 loss anticipated by analysts. Revenue for the quarter reached $211.6 million, significantly higher than the $195.2 million expected by analysts and up from $174.2 million a year earlier.

Investors responded positively to the company's 2026 revenue guidance ranging from $840 million to $870 million, which aligns closely with the $861.4 million analyst consensus estimate, indicating confidence in future growth prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1141429137?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 23:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141429137","market":"hk","top_or_hot":-1,"title":"Stock Track | Supernus Pharmaceuticals Soars 8.22% Intraday on Better-Than-Expected Q4 Results and Strong Guidance","media":"Stock Track","content":"<p>Supernus Pharmaceuticals' stock surged 8.22% during intraday trading on Wednesday, driven by the company's fourth-quarter financial results that exceeded analyst expectations and optimistic revenue guidance for 2026.</p><p>The pharmaceutical company reported a Q4 loss of $0.07 per diluted share, which was better than the $0.08 loss anticipated by analysts. Revenue for the quarter reached $211.6 million, significantly higher than the $195.2 million expected by analysts and up from $174.2 million a year earlier.</p><p>Investors responded positively to the company's 2026 revenue guidance ranging from $840 million to $870 million, which aligns closely with the $861.4 million analyst consensus estimate, indicating confidence in future growth prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Supernus Pharmaceuticals Soars 8.22% Intraday on Better-Than-Expected Q4 Results and Strong Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Supernus Pharmaceuticals Soars 8.22% Intraday on Better-Than-Expected Q4 Results and Strong Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-25 23:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Supernus Pharmaceuticals' stock surged 8.22% during intraday trading on Wednesday, driven by the company's fourth-quarter financial results that exceeded analyst expectations and optimistic revenue guidance for 2026.</p><p>The pharmaceutical company reported a Q4 loss of $0.07 per diluted share, which was better than the $0.08 loss anticipated by analysts. Revenue for the quarter reached $211.6 million, significantly higher than the $195.2 million expected by analysts and up from $174.2 million a year earlier.</p><p>Investors responded positively to the company's 2026 revenue guidance ranging from $840 million to $870 million, which aligns closely with the $861.4 million analyst consensus estimate, indicating confidence in future growth prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SUPN","symbol_name":"Supernus Pharmaceuticals","start_time":0,"source_url":"","article_id":"1141429137","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141429137","pubTimestamp":1772033098,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Supernus Pharmaceuticals' stock surged 8.22% during intraday trading on Wednesday, driven by the company's fourth-quarter financial results that exceeded analyst expectations and optimistic revenue...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SUPN":"Supernus Pharmaceuticals"},"translate_title":"个股赛道|Supernus Pharmaceuticals盘中大涨8.22%，Q4业绩好于预期，指引强劲","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SUPN":1},"content_text":"Supernus Pharmaceuticals' stock surged 8.22% during intraday trading on Wednesday, driven by the company's fourth-quarter financial results that exceeded analyst expectations and optimistic revenue guidance for 2026.The pharmaceutical company reported a Q4 loss of $0.07 per diluted share, which was better than the $0.08 loss anticipated by analysts. Revenue for the quarter reached $211.6 million, significantly higher than the $195.2 million expected by analysts and up from $174.2 million a year earlier.Investors responded positively to the company's 2026 revenue guidance ranging from $840 million to $870 million, which aligns closely with the $861.4 million analyst consensus estimate, indicating confidence in future growth prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1141429137","isCrawlerRequest":true}